Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers

Silexion Therapeutics Corp

2025-Q2 EPS reported $8.21

Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.
Cash $3.5M at June 30, 2025 (up from $1.2M at Dec 31, 2024); warrant exercise raised ~$1.8M in July.
Preclinical: SIL204 achieved 94% inhibition in pancreatic, 90% in colorectal, up to 97% in KRAS Q61H pancreatic cancer cells.
Strategic collaboration with Catalent for formulation development; Phase 2/3 trial on track for H1 2026.
Nasdaq listing maintained after 1-for-15 reverse split and panel decision; pursuing $2.5M equity threshold.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.